Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Spinal Cord Neoplasms 1 Pinealoma 1 Lymphoma, Follicular 1 Glioma 1 Glioblastoma 1 Choroid Plexus Carcinoma 1 Central Nervous System Neoplasms 1

Interventions

Rituximab 90 Cyclophosphamide 30 Lenalidomide 28 Bendamustine Hydrochloride 24 Prednisone 20 Vincristine 19 obinutuzumab 17 Doxorubicin 16 fludarabine 14 ibrutinib 13 tazemetostat 9 idelalisib 9 Deoxycholic Acid 9 parsaclisib 8 Prednisolone 8 zanubrutinib 7 venetoclax 7 tofacitinib 7 tisagenlecleucel 5 pembrolizumab 5 ofatumumab 5 ibritumomab tiuxetan 5 duvelisib 5 Gemcitabine 5 Bortezomib 5 durvalumab 4 aflibercept 4 R-CHOP protocol 4 Methylprednisolone 4 Methotrexate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, Follicular × perillyl alcohol × Clear all

NCT05023018 2026-03-02

NEO100 and High-Grade Meningioma

Neonc Technologies, Inc.

Phase 2 Recruiting

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡